Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Study of ABBV-383 in Relapsed or Refractory Multiple Myeloma (Subcutaneous and Intravenous Administration)
jRCT2041240056Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of etentamig in multiple myeloma (MM) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants Experiencing Cytokine Release Syndrome (CRS) Events, Percentage of Participants Experiencing Immune Cell-Associated Neurotoxicity Syndrome (ICANS) Events and 4 more. Started Sep 2024; status: active, not recruiting.
02
Drugs
etentamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2041240056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240056.